More GI bleeding seen in atrial fibrillation patients on rivaroxaban than warfarin

Patients with atrial fibrillation (AF) experienced more major and non-major clinically relevant GI bleeding when taking rivaroxaban than patients taking warfarin.

As part of the ROCKET AF trial, researchers from multiple institutions, including Harvard Medical School; Mount Sinai Medical Center; Janssen Research & Development; and Bayer HealthCare Pharmaceuticals, randomized 14,264 patients with nonvalvular AF to receive either or dose-adjusted .

Post-hoc analysis was performed on all patients while receiving study medication until 2 days after the last dose.

Results showed that GI bleeding events (upper, lower, rectal) occurred more frequently in patients receiving rivaroxaban (n=394) than warfarin (n=290). In addition, major and nonmajor, clinically relevant bleeding occurred more frequently with rivaroxaban use than warfarin use.

However, there were fewer fatal GI bleeds with rivaroxaban and the absolute fatality rate was very low.

This study was presented during CHEST 2012, the annual meeting of the American College of Chest Physicians, held October 20 – 25, in Atlanta, Georgia.

add to favorites email to friend print save as pdf

Related Stories

Stroke risk high when anti-clotting drugs stopped

Apr 25, 2012

Some patients with irregular heartbeats who are taken off anti-clotting medication face a high risk of stroke or blood clotting within a month, according to new research presented at the American Heart Association's Emerging ...

Recommended for you

NT-proBNP modestly improves CVD risk prediction in women

Oct 24, 2014

(HealthDay)—N-terminal pro-B-type natriuretic peptide (NT-proBNP) modestly improves cardiovascular disease (CVD) risk prediction for women, according to a study published in the Oct. 28 issue of the Journal of ...

User comments